Sugemalimab
- Generic Name
- Sugemalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2256084-03-2
- Unique Ingredient Identifier
- 90IQR2I6TR
- Background
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma. It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL and or...
- Indication
用于联合培美曲塞和卡铂用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的转移性非鳞状非小细胞肺癌患者的一线治疗，以及联合紫杉醇和卡铂用于转移性鳞状非小细胞肺癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 560
- Registration Number
- NCT06617416
- Locations
- 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 45
- Registration Number
- NCT06217757
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 346
- Registration Number
- NCT05623267
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
- Conditions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05131438
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT04472858
- Locations
- 🇨🇳
Shanghai Eastern Hospital, Shanghai, Shanghai, China
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT04421352
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04200404
- Locations
- 🇦🇺
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
A Study of CS1001 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03744403
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 259
- Registration Number
- NCT03312842
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.